The Role of Phosphodiesterase Type 5 Inhibitors in the Management of Premature Ejaculation: A Critical Analysis of Basic Science and Clinical Data

European Urology

Volumn 52, Issue 5, 2007, Pages 1331-1339

  Chen, Juza ^a   Keren Paz, Gal ^a   Bar Yosef, Yuval ^a   Matzkin, Haim ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cyclic guanosine monophosphate; Nitric oxide; Phosphodiesterase 5 inhibitors; Premature ejaculation; Rapid ejaculation; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ANESTHETIC AGENT; CLOMIPRAMINE; EMLA; LIDOCAINE; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADJUVANT THERAPY; ADRENERGIC TRANSMISSION; ANALGESIA; ANXIETY; CLINICAL MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG MECHANISM; FLUSHING; HEADACHE; HUMAN; MEDICAL RESEARCH; MEDLINE; MONOTHERAPY; NOSE CONGESTION; PATHOPHYSIOLOGY; PENIS ERECTION; PREMATURE EJACULATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEMINAL VESICLE; SEXUAL SATISFACTION; SIDE EFFECT; VAS DEFERENS;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EJACULATION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 34548839874     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.005     Document Type: Review

References (59)

1. Read S., King M., and Watson J. Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. J Public Health Med 19 (1997) 387-391
2. Porst H., Montorsi F., Rosen R.C., Gaynor L., Grupe S., and Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 51 (2007) 816-824
3. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR (2000), American Psychiatric Association, Washington, DC
4. Waldinger M.D., and Schweitzer D.H. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II: proposals for DSM-V and ICD-11. J Sex Med 3 (2006) 693-705
5. Shabsigh R. Diagnosing premature ejaculation: a review. J Sex Med 3 Suppl 4 (2006) 318-323
6. Waldinger M.D. The neurobiological approach to premature ejaculation. J Urol 168 (2002) 2359-2367
7. McMahon C.G., Abdo C., Incrocci L., et al. Disorders of orgasm and ejaculation in men. J Sex Med 1 (2004) 58-65
8. Giuliano F., and Clément P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol 50 (2006) 454-466
9. Waldinger M.D., and Olivier B. Utility of selective serotonin reuptake inhibitors in premature ejaculation. Curr Opin Investig Drugs 5 (2004) 743-747
10. Haensel S.M., Mos J., Olivier B., and Slob A.K. Sex behavior of male and female Wistar rats affected by the serotonin agonist 8-OH-DPAT. Pharmacol Biochem Behav 40 (1991) 221-228
11. Sato Y., Horita H., Kurohata T., Adachi H., and Tsukamoto T. Effect of the nitric oxide level in the medial preoptic area on male copulatory behavior in rats. Am J Physiol 274 (1998) R243-R247
12. Donatucci C.F. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med 3 Suppl 4 (2006) 303-308
13. Kaplan H.S., Kohl R.N., Pomeroy W.B., Offit A.K., and Hogan B. Group treatment of premature ejaculation. Arch Sex Behav 3 (1974) 443-452
14. Screponi E., Carosa E., Di Stasi S.M., Pepe M., Carruba G., and Jannini E.A. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 58 (2001) 198-202
15. Atmaca M., Kuloglu M., Tezcan E., Semercioz A., Ustundag B., and Ayar A. Serum leptin levels in patients with premature ejaculation. Arch Androl 48 (2002) 345-350
16. Carani C., Isidori A.M., Granata A., et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90 (2005) 6472-6479
17. Waldinger M.D., Rietschel M., Nothen M.M., Hengeveld M.W., and Olivier B. Familial occurrence of primary premature ejaculation. Psychiatr Genet 8 (1998) 37-40
18. Hatzimouratidis K., and Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 51 (2007) 75-89
19. McMahon C.G., Stuckey B.G., Andersen M., et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2 (2005) 368-375
20. Atan A., Basar M.M., Tuncel A., Ferhat M., Agras K., and Tekdogan U. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology 67 (2006) 388-391
21. Abdel-Hamid I.A., El Naggar E.A., and El Gilany A.H. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 13 (2001) 41-45
22. Salonia A., Maga T., Colombo R., et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 168 (2002) 2486-2489
23. Chen J., Mabjeesh N.J., Matzkin H., and Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 61 (2003) 197-200
24. Sommer F., Klotz T., and Mathers M.J. Treatment of premature ejaculation: a comparative vardenafil and SSRI crossover study. J Urol 173 Suppl (2005) 202 (abstract no. 741)
25. Mattos R.M., and Lucon A.M. Tadalafil and slow-release fluoxetine in premature ejaculation-a prospective study. J Urol 173 Suppl (2005) 202 (abstract no. 880)
26. Sato Y., Christ G.J., Horita H., Adachi H., Suzuki N., and Tsukamoto T. The effects of alterations in nitric oxide levels in the paraventricular nucleus on copulatory behavior and reflexive erections in male rats. J Urol 162 (1999) 2182-2185
27. Castellano M., Rizzoni D., Beschi M., et al. Relationship between sympathetic nervous system activity, baroreflex and cardiovascular effects after acute nitric oxide synthesis inhibition in humans. J Hypertens 13 (1995) 1153-1161
28. Krukoff T.L. Central regulation of autonomic function: no brakes?. Clin Exp Pharmacol Physiol 25 (1998) 474-478
29. Pfaus J.G. Neurobiology of sexual behavior. Curr Opin Neurobiol 9 (1999) 751-758
30. Loughney K., Hill T.R., Florio V.A., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216 (1998) 139-147
31. Schultheiss D., Muller S.V., Nager W., et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 19 (2001) 46-50
32. Sato Y., Zhao W., and Christ G.J. Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. Am J Physiol Regul Integr Comp Physiol 281 (2001) R269-R278
33. Prickaerts J., van Staveren W.C., Sik A., et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113 (2002) 351-361
34. Jen P.Y., Dixon J.S., and Gosling J.A. Co-localization of nitric oxide synthase, neuropeptides and tyrosine hydroxylase in nerves supplying the human post-natal vas deferens and seminal vesicle. Br J Urol 80 (1997) 291-299
35. Dixon J.S., and Jen P.Y. Development of nerves containing nitric oxide synthase in the human male urogenital organs. Br J Urol 76 (1995) 719-725
36. Hedlund P., Ekstrom P., Larsson B., Alm P., and Andersson K.E. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63 (1997) 115-126
37. Kaminski H.J., and Andrade F.H. Nitric oxide: biologic effects on muscle and role in muscle diseases. Neuromuscul Disord 11 (2001) 517-524
38. Hull E.M., Lumley L.A., Matuszewich L., Dominguez J., Moses J., and Lorrain D.S. The roles of nitric oxide in sexual function of male rats. Neuropharmacology 33 (1994) 1499-1504
39. Bialy M., Beck J., Abramczyk P., Trzebski A., and Przybylski J. Sexual behavior in male rats after nitric oxide synthesis inhibition. Physiol Behav 60 (1996) 139-143
40. 2+ influx in guinea-pig vas deferens. Exp Physiol 85 (2000) 387-398
41. Bultmann R., Klebroff W., and Starke K. Nucleotide-evoked relaxation of rat vas deferens: possible mechanisms. Eur J Pharmacol 436 (2002) 135-143
42. Kriegsfeld L.J., Demas G.E., Huang P.L., Burnett A.L., and Nelson R.J. Ejaculatory abnormalities in mice lacking the gene for endothelial nitric oxide synthase (eNOS-/-). Physiol Behav 67 (1999) 561-566
43. Schultz K., Schultz K., and Schultz G. Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens. Nature 265 (1977) 750-751
44. Axelsson K.L., Andersson R.G., and Wikberg J.E. Effect of cGMP derivatives on contraction relaxation cycle, release of norepinephrine and protein kinase activity in guinea pig vas deferens. Acta Pharmacol Toxicol (Copenh) 47 (1980) 328-334
45. Mancina R., Filippi S., and Marini M. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 11 (2005) 107-115
46. Djoseland O., Gordeladze J.O., Hoglo S., Halse J.I., and Haugen H.N. Evidence for androgen-dependent phosphodiesterase activity in rat seminal vesicle and epididymis. Int J Androl 3 (1980) 363-366
47. Yanaka N., Kotera J., Ohtsuka A., et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 255 (1998) 391-399
48. Ückert S., Oelke M., Stief C.G., Andersson K.-E., Jonas U., and Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49 (2006) 740-745
49. Frith D., and Gibson A. Sildenafil citrate on nitrergic transmission in anococcygeus muscles from the urogenital system of male and female mice. Eur J Pharmacol 400 (2000) 305-312
50. Takeda M., Tang R., Shapiro E., Burnett A.L., and Lepor H. Effects of nitric oxide on human and canine prostates. Urology 45 (1995) 440-446
51. Medina P., Segarra G., Torondel B., et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 131 (2000) 871-874
52. Jain N.K., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res 909 (2001) 170-178
53. Vanden Broucke H., Everaert K., Peersman W., Claes H., Vanderschueren D., and Van Kampen M. Ejaculation latency times and their relationship to penile sensitivity in men with normal sexual function. J Urol 177 (2007) 237-240
54. Kameya Y., Deguchi A., and Yokota Y. Analysis of measured values of ejaculation time in healthy males. J Sex Marital Ther 23 (1997) 25-28
55. Hirsch M., Donatucci C., Glina S., Montague D., Montorsi F., and Wyllie M. Standards for clinical trials in male sexual dysfunction: erectile dysfunction and rapid ejaculation. J Sex Med 1 (2004) 87-91
56. Althof S.E., Corty E.W., Levine S.B., et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53 (1999) 793-799
57. Bar-Yosef Y., Greenstein A., Matzkin H., and Chen J. Efficacy of sildenafil citrate in the treatment of premature ejaculation-a double blind, placebo-controlled crossover study. J Urol 177 Suppl (2007) MP34
58. Althof S., Rosen R., Symonds T., Mundayat R., May K., and Abraham L. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 3 (2006) 465-475
59. McMahon C.G., McMahon C.N., Leow L.J., and Winestock C.G. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 98 (2006) 259-272